Arteris (AIP) has opened Q1 2026 with revenue of US$22.9 million and a basic EPS loss of US$0.17, setting the tone for another growth focused but loss making quarter. The company has seen quarterly revenue move from US$16.5 million in Q1 2025 to US$22.9 million in Q1 2026, while basic EPS losses have ranged between US$0.21 and US$0.17 over the same period, which keeps the spotlight firmly on how efficiently that top line is being converted. With revenue expansion set against ongoing losses, the focus this quarter is on whether margins are starting to tighten or remain under pressure.

See our full analysis for Arteris.

With the latest numbers on the table, the next step is to see how this print lines up with the main bullish and bearish narratives investors have been following around Arteris and where those stories may need updating.

Losses Narrow, But Remain Heavy On TTM Basis

• On a trailing twelve month basis, Arteris reported total revenue of US$76.98 million and a net loss of US$34.58 million, with basic EPS over that period at a loss of US$0.80.
• Bears point out that the business has stayed loss making even as revenue has climbed, and the latest trailing twelve month figures keep that concern alive.
  • Over the last five years, losses have risen at about 18.1% per year, which lines up with the current trailing twelve month net loss of US$34.58 million and supports the cautious view that scale has not yet translated into earnings.
  • Consensus narrative highlights rising R&D and field engineering spend as a pressure point, and the fact that trailing twelve month EPS is still a loss of US$0.80 suggests those higher costs are not yet being offset by the revenue base of US$76.98 million.

Skeptics argue that this kind of loss profile can persist for a long time, so it is worth seeing exactly how they frame the long term risks in their detailed thesis before deciding how much weight to put on this quarter's numbers 🐻 Arteris Bear Case.

Q1 Margins Tell A Mixed Story

• For Q1 2026, Arteris generated revenue of US$22.94 million and recorded a net loss of US$7.96 million, with a basic EPS loss of US$0.17 compared with losses between US$0.20 and US$0.22 in each quarter of 2025.
• Supporters of the bullish view focus on product traction and design wins, and the recent pattern of quarterly EPS losses provides a check on that optimism.
  • Bullish narratives talk about large customers adopting FlexGen and Magillem Packaging and point to this as a route to stronger margins, yet net losses have stayed close to US$8 million per quarter from Q1 2025 through Q1 2026 even as revenue moved from US$16.53 million to US$22.94 million.
  • Backers of the growth story highlight accelerating IP outsourcing and a larger addressable market, but the fact that every quarter in the table still shows a basic EPS loss near US$0.20 suggests that any margin lift from those wins is not visible in these numbers yet.

Bulls argue these Q1 figures are the early stages of a longer ramp, so if you want to see how they connect wins like AMD to future earnings power it is worth reading their full case 🐂 Arteris Bull Case.

Rich Valuation Versus Cash Flow Reality

• The stock trades at US$35.55, which sits well above the stated DCF fair value of US$10.32 and on a P/S of about 21.3x compared with 3.5x for the wider US Software industry and 2.0x for peers.
• Consensus narrative flags this valuation gap as a key tension, and the current earnings profile adds weight to that discussion.
  • Analysts expect revenue to grow around 23.2% per year, but at the same time they do not forecast a move into profitability over the next three years, which means the high P/S multiple is supported by top line expectations rather than current earnings from the US$76.98 million trailing twelve month revenue base.
  • Critics highlight that the share price is not only well above the DCF fair value of US$10.32 but also sits above the single allowed analyst price target of US$37.75 by a small margin, and when combined with persistent trailing twelve month losses of US$34.58 million, this underlines why some investors see more risk if growth or margins fall short of those expectations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arteris on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, that is the point. Investors are weighing both sides right now. Take a moment to review the underlying data yourself, consider how much risk and reward you are comfortable with, then see the 1 key reward and 2 important warning signs

Explore Alternatives

Arteris is still reporting sizeable losses alongside a relatively rich P/S multiple, so the current valuation relies heavily on expectations rather than proven profitability.

If you want stocks where price better reflects underlying earnings power and balance sheet strength right now, check out 47 high quality undervalued stocks to compare ideas side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.